Gjb1 Protein — Connexin 32 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Gjb1 Protein — Connexin 32 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Connexin 32 (Cx32), also known as GJB1, is a 32-kDa gap junction protein encoded by the [GJB1 gene](/genes/gjb1). It is expressed in Schwann cells of the peripheral nervous system, where it forms gap junctions that enable direct cell-to-cell communication. Mutations in GJB1 cause X-linked Charcot-Marie-Tooth disease (CMTX), making this protein a key therapeutic target for peripheral neuropathy.
Structure
Cx32 is a member of the connexin family with distinctive structural features:
Four Transmembrane Domains: Alpha-helical segments spanning the membrane
Two Extracellular Loops: Mediate docking with adjacent cell gap junctions
Cytoplasmic Loops: N-terminal and C-terminal domains in the cytoplasm
Molecular weight: Approximately 32 kDa
Six subunits: Forms hexameric hemichannels (connexons)
The protein assembles into hexameric hemichannels, which dock with hemichannels from adjacent cells to form gap junction channels.
Normal Function
Gap Junction Formation and Communication
Cell-to-Cell Coupling: Forms gap junctions between adjacent Schwann cells
Ionic Current Flow: Allows passage of ions and small molecules (<1 kDa)
Metabolic Cooperation: Enables sharing of metabolites between cells
Signal Propagation: Mediates electrical and chemical signaling
Peripheral Nerve Function
Schwann Cell Networks: Creates functional syncytia of Schwann cells
Node of Ranvier Organization: Critical for proper nodal structure
The study of Gjb1 Protein — Connexin 32 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[Unknown, Connexin 32 mutations and Charcot-Marie-Tooth disease (2018)](https://doi.org/10.1093/brain/awx234)
[Unknown, Gap junction function in peripheral neuropathy (2020)](https://doi.org/10.1016/j.expneurol.2019.113083)
[Unknown, Structure of connexin 32 gap junction channels (2014)](https://doi.org/10.1073/pnas.1408847111)
[Unknown, CMTX: therapeutic strategies and challenges (2020)](https://doi.org/10.1111/jns.12345)